Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News

Author: Maureen Meehan | April 30, 2024 01:50pm

The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, the Associated Press reported on Tuesday early afternoon, calling it a "historic shift to generations of American drug policy that could have wide ripple-effects across the country."

The DEA's proposal, which still must be reviewed by the White House Office of Management and Budget, says the outlet, would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than some of the nation's most dangerous drugs. However, it would not legalize marijuana outright for recreational use.

The agency's move, confirmed to the AP on Tuesday by five people familiar with the matter who spoke on the condition of anonymity to discuss the sensitive regulatory review, clears the last significant regulatory hurdle before the agency's biggest policy change in over 50 years can take effect.

Once OMB signs off, the DEA is expected to take public comment on the plan to move marijuana from its current classification as a Schedule I drug, which it occupies along such dangerous drugs as heroin and LSD.

Also Read: EXCLUSIVE: How Dreka Gates Transforms Cannabis Perceptions

Reclassification would move cannabis to Schedule III, following a recommendation from the Deptment of Health and Human Services to do this very thing. After the public-comment period, the agency would publish the final rule.

Cannabis stocks are up sharply with the news. The AdviserShares Pure U.S Cannabis ETF (NYSE:MSOS) was up by 22.8%.

If you are interested in the financial outcomes of the cannabis industry, then you might be interested in attending Benzinga’s Cannabis Capital Conference in Chicago on Oct. 8-9. Network with key industry players, hear from the top operators, and close deals that will shape the future. Act now— spots are filling fast. Get your tickets here.

More Coverage And Reactions On Benzinga Cannabis

Now Read: Revenue Down, Margins Up: Lifeist’s Q1 Financial Results Show Focus On Premium Products Curbed Revenue Drop

Image generated using artificial intelligence via Midjourney.

Posted In: MSOS